FRX: Analysis & Opinions

  1. Canada Approves Forest's Bystolic - Analyst Blog

    January 22, 2013
    Forest Laboratories, Inc. (FRX) recently announced the Canadian approval of its hypertension treatment, Bystolic ...
  2. Should Third Quarter Results From Forest Laboratories ...

    January 17, 2013
    Forest Labs' miss doesn't seem like a thesis-changing event.
  3. Loss Widens at IRWD on Higher Costs - Analyst Blog

    January 16, 2013
    Ironwood Pharmaceuticals, Inc.'s (IRWD) fourth-quarter 2012 loss of 41 cents per share compared unfavorably with the ...
  4. Market to Remain Tentative - Analyst Blog

    January 15, 2013
    A strong retail sales reading, weak economic growth in Germany, and reassuring words out of Ben Bernanke Monday ...
  5. Ahead of Wall Street - January 15, 2012 - Ahead of Wall ...

    January 15, 2013
    Tuesday, January 15, 2013 A strong retail sales reading, weak economic growth in Germany, and reassuring words ...
  6. Forest Revs Down, Swings to Loss - Analyst Blog

    January 15, 2013
    Forest Laboratories, Inc. (FRX) reported a third quarter fiscal 2013 loss of 29 cents per share, well below the ...
  7. Straddling Earnings Season - Know Your Options

    January 10, 2013
    With earnings season having just gotten started, here's an options strategy that's perfect for a company about to ...
  8. Forest Settles with Glenmark - Analyst Blog

    January 09, 2013
    Forest Laboratories, Inc. (FRX) recently entered into a settlement agreement with Glenmark Pharmaceuticals Ltd., ...
  9. Alcoa Has Improved, But It's Still In The Aluminum Business

    January 09, 2013
    Although undervalued, Alcoa is still an aluminum company.
  10. Ironwood Winds Up Debt Offering - Analyst Blog

    January 07, 2013
    Entrepreneurial pharmaceutical company, Ironwood Pharmaceuticals, Inc. (IRWD) recently announced that it has ...
  11. Positive Results on SGYP Candidate - Analyst Blog

    January 03, 2013
    Synergy Pharmaceuticals (SGYP) recently presented positive results from a phase IIb/III study on its chronic ...
  12. Ironwood Pharma Upped to Strong Buy - Analyst Blog

    January 03, 2013
    On January 2, 2013, Zacks Investment Research upgraded Ironwood Pharmaceuticals, Inc.'s (IRWD) to a Zacks #1 Rank ...
  13. Pipeline Progress at Synergy Pharma - Analyst Blog

    December 31, 2012
    Synergy Pharmaceuticals (SGYP) recently initiated a phase IIb study with plecanatide for the treatment of patients ...
  14. Forest Labs-Glenmark Tie Up - Analyst Blog

    December 31, 2012
    Forest Labs (FRX) and Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited ...
  15. Ironwood Anxiety Drug in Phase I - Analyst Blog

    December 27, 2012
    Ironwood Pharmaceuticals Inc. (IRWD) recently commenced a phase I study in the US with its anti-anxiety candidate, ...
  16. Good News for AstraZeneca - Analyst Blog

    December 19, 2012
    Good news flowed in at AstraZeneca (AZN) from Europe when the Committee for Medicinal Products for Human Use (CHMP) ...
  17. Forest Launches Two Products - Analyst Blog

    December 19, 2012
    Forest Laboratories, Inc. (FRX) and partner Ironwood Pharmaceuticals, Inc. (IRWD) recently launched Linzess ...
  18. Forest Files Cariprazine NDA - Analyst Blog

    December 04, 2012
    Forest Laboratories, Inc., (FRX) and Gedeon Richter Plc. recently announced the submission of a new drug application ...
  19. EU Approval for Ironwood's Constella - Analyst Blog

    November 30, 2012
    The European Commission recently granted approval to Ironwood Pharmaceuticals Inc. (IRWD) and partner Almirall, ...
  20. Pfizer's Lyrica Scores in Study - Analyst Blog

    November 21, 2012
    Pfizer Inc. (PFE) recently announced positive top-line data on its once-daily formulation of Lyrica (pregabalin). ...
Marketplace
Trading Center